[go: up one dir, main page]

AR111699A1 - Composición farmacéutica que comprende betahistina - Google Patents

Composición farmacéutica que comprende betahistina

Info

Publication number
AR111699A1
AR111699A1 ARP180100254A ARP180100254A AR111699A1 AR 111699 A1 AR111699 A1 AR 111699A1 AR P180100254 A ARP180100254 A AR P180100254A AR P180100254 A ARP180100254 A AR P180100254A AR 111699 A1 AR111699 A1 AR 111699A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
betahistina
composition including
enhancing agent
viscosity enhancing
Prior art date
Application number
ARP180100254A
Other languages
English (en)
Inventor
Thomas Meyer
Christopher John Wraight
Original Assignee
Otolanum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otolanum Ag filed Critical Otolanum Ag
Publication of AR111699A1 publication Critical patent/AR111699A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica para administración intranasal a un paciente humano, que comprende una solución o suspensión de una cantidad terapéuticamente eficaz de betahistina o una sal farmacéuticamente aceptable de esta y un agente potenciador de la viscosidad. Reivindicación 9: La composición farmacéutica de la reivindicación 8, donde el agente potenciador de la viscosidad es polivinil pirrolidona.
ARP180100254A 2017-02-02 2018-02-02 Composición farmacéutica que comprende betahistina AR111699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02

Publications (1)

Publication Number Publication Date
AR111699A1 true AR111699A1 (es) 2019-08-14

Family

ID=61187302

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100254A AR111699A1 (es) 2017-02-02 2018-02-02 Composición farmacéutica que comprende betahistina

Country Status (33)

Country Link
US (2) US10456386B2 (es)
EP (2) EP3474850B1 (es)
JP (3) JP7714323B2 (es)
KR (1) KR102653545B1 (es)
CN (2) CN118356397A (es)
AR (1) AR111699A1 (es)
AU (1) AU2018216970B2 (es)
CA (1) CA3051725A1 (es)
CL (1) CL2019002145A1 (es)
CO (1) CO2019008657A2 (es)
DK (2) DK3698791T3 (es)
EA (1) EA201991817A1 (es)
ES (2) ES2969301T3 (es)
FI (1) FI3698791T3 (es)
HR (2) HRP20231706T1 (es)
HU (2) HUE050829T2 (es)
IL (1) IL268353B2 (es)
LT (2) LT3474850T (es)
MA (1) MA46778B1 (es)
MX (1) MX381932B (es)
MY (1) MY196333A (es)
NZ (1) NZ755931A (es)
PH (1) PH12019501785B1 (es)
PL (2) PL3698791T3 (es)
PT (2) PT3698791T (es)
RS (2) RS60554B1 (es)
SA (1) SA519402324B1 (es)
SG (1) SG11201906980YA (es)
SI (2) SI3474850T1 (es)
TN (1) TN2019000220A1 (es)
TW (1) TWI760429B (es)
WO (1) WO2018141922A1 (es)
ZA (1) ZA201904955B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (en) * 2017-03-22 2018-09-27 Franz, Lilian Ann Treatment method
CA3179806A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Nasal spray formulation with moisturizing benefits
EP4138862A4 (en) * 2020-04-22 2023-10-25 SaNOtize Research and Development Corp. COMPOSITIONS AND METHODS FOR TREATING UPPER AIRWAY INFECTIONS

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (es) 1977-07-22 1981-03-20 Cherqui Jean
IT1229237B (it) * 1989-05-08 1991-07-26 Prodotti Formenti Sali di (2-(piridil)etil) metilammina
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
DE60303854T2 (de) 2003-11-11 2006-08-10 Mattern, Udo Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
CA2553309A1 (en) 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
WO2007022345A2 (en) * 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US8119668B2 (en) * 2005-12-23 2012-02-21 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
JP2011507895A (ja) 2007-12-21 2011-03-10 シェーリング−プラウ ヘルスケア プロダクツ，インコーポレイテッド オキシメタゾリンの増強された光安定化
KR20130097813A (ko) * 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
CN102046170B (zh) * 2008-05-27 2012-11-28 墨尔本大学 治疗患有咽鼓管功能障碍的哺乳动物的方法
ES2589915T3 (es) * 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
JP2017530195A (ja) 2014-10-03 2017-10-12 ラケシス・バイオサイエンシーズ・リミテッド 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物

Also Published As

Publication number Publication date
MA46778A1 (fr) 2021-04-30
TW201831179A (zh) 2018-09-01
CO2019008657A2 (es) 2020-01-17
CN118356397A (zh) 2024-07-19
SA519402324B1 (ar) 2023-03-16
JP2022051872A (ja) 2022-04-01
SI3474850T1 (sl) 2020-09-30
KR20190116341A (ko) 2019-10-14
TN2019000220A1 (en) 2021-01-07
HRP20231706T1 (hr) 2024-03-15
US20180214432A1 (en) 2018-08-02
ES2969301T3 (es) 2024-05-17
EA201991817A1 (ru) 2020-01-27
AU2018216970B2 (en) 2023-12-21
CA3051725A1 (en) 2018-08-09
DK3474850T3 (da) 2020-08-03
US20200022963A1 (en) 2020-01-23
MA46778B1 (fr) 2022-08-31
US10456386B2 (en) 2019-10-29
HUE050829T2 (hu) 2021-01-28
EP3698791B1 (en) 2023-10-25
DK3698791T3 (da) 2024-01-15
JP2024019731A (ja) 2024-02-09
NZ755931A (en) 2022-07-29
EP3474850A1 (en) 2019-05-01
BR112019015687A2 (pt) 2020-04-28
EP3698791A1 (en) 2020-08-26
PT3698791T (pt) 2024-01-12
RS65099B1 (sr) 2024-02-29
LT3474850T (lt) 2020-08-10
JP7714323B2 (ja) 2025-07-29
PH12019501785B1 (en) 2024-02-28
FI3698791T3 (fi) 2024-01-11
PL3698791T3 (pl) 2024-04-08
SG11201906980YA (en) 2019-08-27
PL3474850T3 (pl) 2020-09-21
PT3474850T (pt) 2020-07-27
LT3698791T (lt) 2024-02-12
SI3698791T1 (sl) 2024-05-31
EP3474850B1 (en) 2020-04-22
IL268353B1 (en) 2023-06-01
TWI760429B (zh) 2022-04-11
ZA201904955B (en) 2021-05-26
KR102653545B1 (ko) 2024-04-04
RS60554B1 (sr) 2020-08-31
CL2019002145A1 (es) 2019-11-04
MX381932B (es) 2025-03-13
HUE065336T2 (hu) 2024-05-28
MX2019008961A (es) 2019-10-15
CN110418643A (zh) 2019-11-05
IL268353A (en) 2019-09-26
HRP20201137T1 (hr) 2021-01-22
JP2020506930A (ja) 2020-03-05
AU2018216970A1 (en) 2019-08-22
MY196333A (en) 2023-03-24
PH12019501785A1 (en) 2020-07-06
WO2018141922A1 (en) 2018-08-09
IL268353B2 (en) 2023-10-01
ES2807798T3 (es) 2021-02-24

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
AR111699A1 (es) Composición farmacéutica que comprende betahistina
PE20190347A1 (es) Formulaciones inyectables fisiologicamente balanceadas de fosnetupitant
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
ITUA20164387A1 (it) Composizione farmaceutica comprendente Cetraria islandica Ach., sodio ialuronato e una soluzione salina per il trattamento di affezioni dell'apparato respiratorio.
CO2020005939A2 (es) Composiciones acuosas que comprenden bilastina y mometasona
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
BR112015031835A8 (pt) agentes terapêuticos, combinação dos referidos agentes e agente terapêutico adicional, uso dos referidos agentes e da referida combinação para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético

Legal Events

Date Code Title Description
FC Refusal